Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peginterferon Alfa-2b and Tenofovir Alafenamide in HBeAg Negative Chronic Hepatitis B
NCT05490836Completed
- Sponsor
- Huashan Hospital
- Start
- Sep 2022
- Primary completion
- May 2026
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
- Countries
- 1
01
Overview
Randomised, open-label trial of peginterferon alfa-2b in Chronic Hepatitis B (CHB) (2 arms), sponsored by Huashan Hospital. Primary endpoint: Rate of HBsAg negative at 48 weeks. Started Sep 2022; status: completed.
02
Drugs
peginterferon alfa-2b
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT05490836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05490836.